A Phase 3 interventional study of Saline and Exendin-9,39 in Healthy and Type 2 Diabetes, sponsored by Adrian Vella. Completed at 1 site in United States. Open to participants aged 25 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-12-26.
Sponsored by Adrian Vella · Phase 3, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 3,308 studies in Diabetes Mellitus, Type 2 with a site in United States — 345 open to participants now, 479 under way, 51 of them phase 3. Diabetes Mellitus, Type 2 · United States.
Among the 3,308 studies in Diabetes Mellitus, Type 2 with a site in United States, this one is the 2,441st largest by enrollment of the 2,961 interventional ones that give a count, is one of 172 that started in 2021, is one of 580 in phase 3, and was the 2,368th registered.
10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →345 of the 3,308 studies in Diabetes Mellitus, Type 2 with a site in United States are open now. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in United States, Puerto Rico
Ages 18+
University of Minnesota · Sites in United States
Ages 30–75
Montefiore Medical Center · Sites in United States
Ages 18–85
Pfizer · Sites in United States
Ages 18+
Eli Lilly and Company · Sites in United States, Singapore
Ages 18–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 25 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
3,308 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 425 · Phase 2 465 · Phase 3 613 · Phase 4 300
First in 1976; this study’s year is marked. 172 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 23 is below the median of 80 across 8,372 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 90 across the 2,961 interventional studies, 128 across the 336 observational. Of the 2,651 that completed or were terminated, 1,166 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
1,489 of 3,308 have an industry lead sponsor. The 10 most frequent:
Adrian Vella is the lead sponsor of 9 studies on the registry; 1 is open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 5 (100%) have results posted.
Adrian Vella has 3 studies filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
189 of the studies in Diabetes Mellitus, Type 2 with a site in United States that are under way reach primary completion within a year, 8 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06858878Phase 3AmgenEfficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT06731075Phase 3Oramed, Ltd.A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus. | 2027-04-25 |
| NCT07220759Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide | 2027-05-12 |
| NCT07817251Phase 3Novo Nordisk A/SResearch Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema | 2027-06-09 |
| NCT06993792Phase 3Eli Lilly and CompanyA Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes | 2027-08 |
Add all 189 to your calendar (.ics) → With an account.
Among the 3,308 studies in Diabetes Mellitus, Type 2 with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
GLP-1 is a hormone made by the body that promotes the production of insulin in response to GLP-1 is produced within the islets expressing prohormone convertase 1/3eating. However, there is increasing evidence that this hormone might help support the body's ability to produce insulin when diabetes develops. The purpose of this study is to determine the effect of endogenous GLP-1 secretion on insulin secretion in people with and without type 2 diabetes.
Accumulating evidence suggests that in rodents and humans GLP-1 is synthesized within islets and may act locally in a paracrine fashion. Indeed, mice with genetic loss of intra-islet GLP-1 exhibit decreased insulin secretion and impaired response to metabolic stressors. 'Pancreatic' GLP-1 may contribute to the effects of DPP-4 inhibitors in rodents and humans. Antagonism of GLP1R with exendin-9,39 during fasting impairs the islet cell response to an I.V. glucose challenge. Islet GLP-1 content is increased in T2DM and in islets from non-diabetic humans exposed to hyperglycemia and Free Fatty Acids. These observations imply that paracrine GLP-1 secretion supports islet function in the presence of glucolipotoxicity. In this experiment we will examine the role of endogenous GLP-1 secretion in people with and without T2DM and during β-cell stress induced by FFA elevation.
Inclusion criteria - non-diabetic subjects:
Exclusion Criteria - non-diabetic subjects:
Inclusion criteria - diabetic subjects:
Exclusion Criteria - diabetic subjects:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Saline infusion
Biological: Saline
Exendin-9,39 infusion
Biological: Exendin-9,39
Induction of acute insulin resistance during Saline infusion
Biological: Saline + Intralipid/Heparin
Induction of acute insulin resistance during Exendin-9,39 infusion
Biological: Exendin-9,39 + Intralipid/Heparin
Saline infused during the study
Exendin-9,39 infused during the study
Saline infused during acute insulin resistance
Exendin-9,39 infused during acute insulin resistance
Change in Fasting Glucagon in the Presence or Absence of Exendin-9,39
Concentrations of glucagon Measured by immunoassay over the -30 to 0 minutes of study. On one study day subjects received saline, on the other exendin-9,39. The infusion commenced at -120 minutes.
Time frame: Average concentration over the -30 to 0 minutes of study
| Milestone | Non-diabetic Subjects | Subjects With Type 2 Diabetes |
|---|---|---|
| Started | 12 | 11 |
| Completed | 12 | 10 |
| Not completed | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 |
Concentrations of glucagon Measured by immunoassay over the -30 to 0 minutes of study. On one study day subjects received saline, on the other exendin-9,39. The infusion commenced at -120 minutes.
| pmol/l | No Diabetes | Type 2 Diabetes |
|---|---|---|
| Saline | 7.4 ± 1.2 | 7.9 ± 0.3 |
| Exendin 9-39 | 7.8 ± 1.1 | 10.2 ± 0.3 |
Collected over The 3 months of participation. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Non-diabetic Subjects Saline | 0/12 (0%) | 0/12 (0%) | 0/12 (0%) |
| Non-diabetic Subjects Exendin-9,39 | 0/12 (0%) | 0/12 (0%) | 0/12 (0%) |
| Non-diabetic Subjects Saline + Intralipid/Heparin | 0/12 (0%) | 0/12 (0%) | 0/12 (0%) |
| Non-diabetic Subjects Exendin-9,39 + Intralipid/Heparin: | 0/12 (0%) | 0/12 (0%) | 0/12 (0%) |
| Type 2 Diabetes Saline | 0/11 (0%) | 0/11 (0%) | 1/11 (9.1%) |
| Type 2 Diabetes Exendin-9,39 | 0/11 (0%) | 0/11 (0%) | 1/11 (9.1%) |
| Event | Non-diabetic Subjects Saline | Non-diabetic Subjects Exendin-9,39 | Non-diabetic Subjects Saline + Intralipid/Heparin | Non-diabetic Subjects Exendin-9,39 + Intralipid/Heparin: | Type 2 Diabetes Saline | Type 2 Diabetes Exendin-9,39 |
|---|---|---|---|---|---|---|
| HyperglycemiaEndocrine disorders | 0/12 | 0/12 | 0/12 | 0/12 | 1/11 | 0/11 |
| IV access lossVascular disorders | 0/12 | 0/12 | 0/12 | 0/12 | 0/11 | 1/11 |
| Age, Continuous(years) | No Diabetes | Type 2 Diabetes | Total |
|---|---|---|---|
| Mean | 54 ± 8 | 58 ± 5 | 56 ± 7 |
| Sex: Female, Male(Participants) | No Diabetes | Type 2 Diabetes | Total |
|---|---|---|---|
| Female | 8 | 8 | 16 |
| Male | 4 | 3 | 7 |
| Race and Ethnicity Not Collected(Participants) | No Diabetes | Type 2 Diabetes | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| Region of Enrollment(participants) | No Diabetes | Type 2 Diabetes | Total |
|---|---|---|---|
| United States | 12 | 11 | 23 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2021 to primary completion in Dec 2022, 20 months.
Results were first posted in Dec 2023, 1 year after primary completion.
Of 87 non-industry phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 47. This study's 20 months is below that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Avexitide
Adrian Vella